DICHLORMID


UNII	E901J4382O
Source	Gaulton A, Kale N, van Westen GJ, Bellis LJ, Bento AP, Davies M, Hersey A, Papadatos G, Forster M, Wege P, Overington JP. A large-scale crop protection bioassay data set. Sci Data. 2015 Jul 7;2:150032. Read more ...


Active Pharmaceutical Ingredients Bioactive chemicals	Exact Similarity SubStructure	Threshold (%) >= 70

Structure


InChI Key	YRMLFORXOOIJDR-UHFFFAOYSA-N
Smiles	ClC(Cl)C(=O)N(CC=C)CC=C
InChI	InChI=1S/C8H11Cl2NO/c1-3-5-11(6-4-2)8(12)7(9)10/h3-4,7H,1-2,5-6H2

Physicochemical Descriptors

Property Name	Value
Molecular Formula	C8H11Cl2NO
Molecular Weight	208.09
AlogP	2.01
Hydrogen Bond Acceptor	1.0
Hydrogen Bond Donor	0.0
Number of Rotational Bond	5.0
Polar Surface Area	20.31
Molecular species	NEUTRAL
Aromatic Rings	0.0
Heavy Atoms	12.0

Assay Description	Organism	Bioactivity
Effect on GST activity in Zea mays (maize) shoot at 50 uM applied to seeds incubated for 5 days by CDNB-based spectrophotometric analysis relative to control	Zea mays	None
Increase in GSH content in Zea mays (maize) root at 50 uM applied to seeds incubated for 5 days by DNTB-based spectrophotometric analysis relative to control	Zea mays	1.65
Increase in GSH content in Zea mays (maize) shoot at 50 uM applied to seeds incubated for 5 days by DNTB-based spectrophotometric analysis relative to control	Zea mays	1.78
Safening activity against acetochlor-induced phytotoxicity against Zea mays (maize) assessed as increase in shoot length at 50 uM applied pre-emergence measured 14 days after treatment relative to acetochlor-treated control	Zea mays	81.0 %
Binding affinity to SafBP receptor in Zea mays (maize) seedlings by [3H]Saf(R-29148) binding assay	Zea mays	10.0 nM	Binding affinity to SafBP receptor in Zea mays (maize) seedlings by [3H]Saf(R-29148) binding assay	Zea mays	10000000.0 nM

Cross References

Resources	Reference
ChEMBL	CHEMBL2251310
FDA SRS	E901J4382O
PubChem	37829
SureChEMBL	SCHEMBL117463

CONTENTS


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).